Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2

(2016) Werner Scheuer et al.   mAbs

The coming of age of engineered multivalent antibodies

(2015) Natalia Nuñez-Prado et al.   DRUG DISCOVERY TODAY

FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin

(2015) Michal Pyzik et al.   JOURNAL OF IMMUNOLOGY

Metal ion interactions with mAbs: Part 1

(2015) Zephania Kwong Glover et al.   mAbs

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells

(2015) Nazzareno Dimasi et al.   MOLECULAR PHARMACEUTICS

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions

(2015) Céline Monnet et al.   Frontiers in Immunology

CD19 and CD32b Differentially Regulate Human B Cell Responsiveness

(2014) J. L. Karnell et al.   JOURNAL OF IMMUNOLOGY

Bispecific antibodies rise again

(2014) Ken Garber   NATURE REVIEWS DRUG DISCOVERY

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa

(2014) A. DiGiandomenico et al.   Science Translational Medicine

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies

(2013) Christoph Spiess et al.   NATURE BIOTECHNOLOGY

A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

(2013) Markus Thomas et al.   PLoS One

MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models

(2012) Ching Leow   INTERNATIONAL JOURNAL OF ONCOLOGY

Mechanisms of resistance to vascular endothelial growth factor blockade

(2011) Shaad E. Abdullah et al.   CANCER

Fragmentation of monoclonal antibodies

(2011) Josef Vlasak et al.   mAbs

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

(2010) H. Hashizume et al.   CANCER RESEARCH

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

(2010) J. L. Brown et al.   MOLECULAR CANCER THERAPEUTICS

The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators

(2009) Nazzareno Dimasi et al.   JOURNAL OF MOLECULAR BIOLOGY

Structural characterization of a human Fc fragment engineered for extended serum half-life

(2009) Vaheh Oganesyan et al.   MOLECULAR IMMUNOLOGY

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

(2009) J. Bostrom et al.   SCIENCE

Structural characterization of a human Fc fragment engineered for lack of effector functions

(2008) Vaheh Oganesyan et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Structural characterization of a mutated, ADCC-enhanced human Fc fragment

(2008) Vaheh Oganesyan et al.   MOLECULAR IMMUNOLOGY